600200.SS

JiangSu WuZhong Pharmaceutical Development Co., Ltd. [600200.SS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

600200.SS Stock Summary

Earnings have grown 14.12% per last year.

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

600200.SS

Top 10 Correlated Stocks

600200.SS

In the News

600200.SS Financial details

Company Rating

Market Cap

8.15B

Income

-18.89M

Revenue

2.15B

Book val./share

Cash/share

Dividend

Dividend %

Employees

1.01K

Optionable

Shortable

Yes

Earnings

30 Oct 2023

P/E

-337.19

Forward P/E

PEG

18.47

P/S

3.02

P/B

3.49

P/C

P/FCF

-21.7

Quick Ratio

1.22

Current Ratio

1.33

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.03

EPS next Y

EPS next Q

EPS this Y

-441.61%

EPS next Y

EPS next 5Y

EPS last 5Y

-22.76%

Revenue last 5Y

3.55%

Revenue Q/Q

-17.62%

EPS Q/Q

2000%

SMA20

-23.16%

SMA50

-53.68%

SMA100

-56.37%

Inst Own

Inst Trans

ROA

ROE

-1%

ROC

Gross Margin

27%

Oper. Margin

Profit Margin

-1%

Payout

-397%

Shs Outstand

Shs Float

Target Price

52W Range

6.9-13.88

52W High

-75.38%

52W Low

-46.67%

RSI

20.85

Rel Volume

0.14

Avg Volume

50.86M

Volume

7.02M

Perf Week

-31.33%

Perf Month

-45.95%

Perf Quarter

-68.29%

Perf Half Y

-69.26%

Beta

0.189

Volatility

0.57%, 0.67%

Prev Close

-10.11%

Price

3.2

Change

-10.11%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 50.86M
Market Capitalization 8.15B
Employee 1.01K
CEO Mr. Qunshan Qian
Headquarters Suzhou,CN
IPO Date 1999-04-01
Website https://www.600200.com

JiangSu WuZhong Pharmaceutical Development Co., Ltd., together with its subsidiaries, engages in pharmaceutical, real estate, and chemical businesses in China. It develops, produces, and sells anti-infective, digestive system, cardiovascular, cerebrovascular, antiviral, vitamin, and hemostatic drugs; and immunomodulations, including biopharmaceuticals, chemical drugs, and modern Chinese medicines. The company offers its products in various forms, such as infusion solutions, water and powder injections, capsules, granules, tablets, emulsions, and oral liquids. It also engages in the research, development, production, and sale of dyes and dye intermediates; and the fields of commercial housing and affordable housing development. The company was founded in 1994 and is based in Suzhou, China.